Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
[Not Available].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heppt Markus V, Hadshiew Ina, Kempf Afra, Melzer Antje, Berking Carola
Аннотация
BACKGROUND: Tirbanibulin is an approved topical treatment for actinic keratosis (AK). This non-interventional study investigated effectiveness and safety of tirbanibulin for AK.
PATIENTS AND METHODS: The prospective KLIR-study was conducted at 58 German dermatology centers (02/2022-09/2023). Patients received tirbanibulin once daily for 5 consecutive days. Lesion count reduction, clearance rates, safety, and treatment satisfaction were assessed at day 57 (visit 3) after treatment. Visits on days 0, 8-29, and 240 allowed for the evaluation of baseline data, local skin reaction (LSR) peaks, and lesion recurrence, respectively.
RESULTS: In total, 545 AK patients were included in the study. The mean number of AK lesions decreased from 5.9 (baseline) to 1.9 at visit 3, representing a 70% lesion count reduction (p < 0.0001). Clearance rates at visit 3 were 37.4% (complete clearance) and 55.0% (partial clearance ≥ 75% reduction). Among patients with complete clearance at visit 3, 21.9% experienced recurrent AK lesions at visit 4. The majority of LSRs were mild or moderate. Erythema (97.6%) was the most common LSR. Overall, 91.5% of patients rated their AK lesions as improved and 99% would consider future tirbanibulin treatment ("definitely", "certainly", "probably", "maybe").
CONCLUSIONS: Tirbanibulin showed high lesion clearance and a high level of acceptance in real-life conditions.
PATIENTS AND METHODS: The prospective KLIR-study was conducted at 58 German dermatology centers (02/2022-09/2023). Patients received tirbanibulin once daily for 5 consecutive days. Lesion count reduction, clearance rates, safety, and treatment satisfaction were assessed at day 57 (visit 3) after treatment. Visits on days 0, 8-29, and 240 allowed for the evaluation of baseline data, local skin reaction (LSR) peaks, and lesion recurrence, respectively.
RESULTS: In total, 545 AK patients were included in the study. The mean number of AK lesions decreased from 5.9 (baseline) to 1.9 at visit 3, representing a 70% lesion count reduction (p < 0.0001). Clearance rates at visit 3 were 37.4% (complete clearance) and 55.0% (partial clearance ≥ 75% reduction). Among patients with complete clearance at visit 3, 21.9% experienced recurrent AK lesions at visit 4. The majority of LSRs were mild or moderate. Erythema (97.6%) was the most common LSR. Overall, 91.5% of patients rated their AK lesions as improved and 99% would consider future tirbanibulin treatment ("definitely", "certainly", "probably", "maybe").
CONCLUSIONS: Tirbanibulin showed high lesion clearance and a high level of acceptance in real-life conditions.